ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate

Stock News

昨天

ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.

The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1108389066"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108389066\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108389066?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108389066","market":"sh","top_or_hot":-1,"title":"ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate","media":"Stock News","content":"<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-03 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1108389066","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108389066","pubTimestamp":1788423398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600079":"ST人福","BK0012":"证金概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","MDTX":"Corgi MediaTek 2x Daily ETF","BK0096":"民营医院","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"ST人福启动新型术后疼痛候选药物II期临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"BMED":1,"PSYK":1},"content_text":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}